Colforsin (Forskolin)

For research use only.

Catalog No.S2449 Synonyms: Coleonol

62 publications

Colforsin (Forskolin) Chemical Structure

CAS No. 66575-29-9

Colforsin (Forskolin, Coleonol) is a ubiquitous activator of eukaryotic adenylyl cyclase (AC) in a wide variety of cell types, commonly used to raise levels of cAMP in the study and research of cell physiology. Forskolin also activates PXR and FXR activity. Forskolin stimulates autophagy.

Size Price Stock Quantity  
10mM (1mL in DMSO) EUR 137 In stock
EUR 108 In stock
EUR 265 In stock
EUR 363 In stock
EUR 560 In stock
EUR 2938 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Colforsin (Forskolin) has been cited by 62 publications

Purity & Quality Control

Choose Selective cAMP Inhibitors

Biological Activity

Description Colforsin (Forskolin, Coleonol) is a ubiquitous activator of eukaryotic adenylyl cyclase (AC) in a wide variety of cell types, commonly used to raise levels of cAMP in the study and research of cell physiology. Forskolin also activates PXR and FXR activity. Forskolin stimulates autophagy.
Targets
Adenylyl cyclase (AC) [1]
(A wide variety of cell types)
In vitro

Forskolin increases cAMP levels in preparations of membranes, cells, or tissues. Forskolin not only activates AC but also interacts with certain other proteins, including glucose transporters and ion channels. Forskolin is able to promote activation of nine different transmembrane iso-forms of AC, albeit with somewhat less efficacy for AC9, which could be used to provides a means to identify and quantify high-affinity binding sites, i.e., G-proteins (Gs)–AC complexes. Activation of s by GPCRs contributes to Forskolin-stimulated cAMP generation in cells because of s-Forskolin potentiation of AC activity. [1] Forskolin stimulates adenylate cyclase activity without interacting with cell surface receptors. Forskolin's potentiation of cAMP in turn inhibits basophil and mast cell degranulation and histamine release, lowers blood pressure and intraocular pressure, inhibits platelet aggregation, promotes vasodilation, bronchodilation, and thyroid hormone secretion, and stimulates lipolysis in fat cells. Forskolin inhibits the binding of platelet-activating factor (PAF), independently of cAMP formation, which may be a result of Forskolin's direct effect on PAF or via interference with PAF binding to receptor sites. Forskolin also appears to have an effect on several membrane transport proteins, and inhibits glucose transport in erythrocytes, adipocytes, platelets, and other cells. Forskolin is used to treat with glaucoma. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HEK293 NXWx[WtoTnWwY4Tpc44hSXO|YYm= M3fTSVExKM7:TR?= M{L4V|YhcA>? NWXacGtPcW6lcnXhd4V{KHCqb4PwbI9zgWyjdHnvckBw\iCxdnXy[ZhxemW|c3XkJGtNUEx|IHH0JHM1OzN? NGSweHIzPjR|NUS5PC=>
Mo-DCs NXPrU241TnWwY4Tpc44hSXO|YYm= NFLXZ2o2OCEQvF2= MkjDNlTjiImq Mnj2dJJwdW:2ZYOgTWwuOjNicILv[JVkfGmxbjDpckB1cGVic4Xw[ZJv[XSjboSgc4Yhgnmvb4PhckB{fGmvdXzheIVlKE2xLVTDd:Kh M3XtT|I3PDF{OUS4
RBMECs  MU\GeY5kfGmxbjDBd5NigQ>? NH\0OYE2yqEQvF2= NVK1R|E4OcLiaB?= NFfocldjdG:la4OgeIhmKFKjY{GgbY5i[3SrdnH0bY9vKGmwZIXj[YQh[nliRV3BVE1KUQ>? MXKyOlM2QDB|OR?=
INA-6 NIDyd|FE\WyuIG\pZYJqdGm2eTDBd5NigQ>? Mk\LNE0yODBizszN M1m0dVcz6oDLaB?= NY\OR2l1cW6mdXPld{Bk\WyuIHTlZZRpKGSxc3Wg[IVx\W6mZX70cJk> M{\Q[lI3OzB4NkK0
OPM-2 MmPvR4VtdCCYaXHibYxqfHliQYPzZZk> MmrMNE0yODBizszN NF3lbYY4OuLCiXi= NH\GfFNqdmS3Y3XzJINmdGxiZHXheIgh\G:|ZTDk[ZBmdmSnboTsfS=> NYXEOXFLOjZ|ME[2NlQ>
U266 NWHKcJRYS2WubDDWbYFjcWyrdImgRZN{[Xl? NXfTc4E2OC1zMECg{txO NITUOVM4OuLCiXi= NHXCdlFqdmS3Y3XzJINmdGxiZHXheIgh\G:|ZTDk[ZBmdmSnboTsfS=> NUiz[INZOjZ|ME[2NlQ>
H929 MkPnR4VtdCCYaXHibYxqfHliQYPzZZk> M1zh[FAuOTByIN88US=> M1j1TFcz6oDLaB?= M3L6[4lv\HWlZYOgZ4VtdCCmZXH0bEBld3OnIHTldIVv\GWwdHz5 MlO0NlY{ODZ4MkS=
RPMI 8226 M2\lOGNmdGxiVnnhZoltcXS7IFHzd4F6 MWqwMVExOCEQvF2= MUS3NwKBkWh? NXPWXppZcW6mdXPld{Bk\WyuIHTlZZRpKGSxc3Wg[IVx\W6mZX70cJk> NUfkWHNoOjZ|ME[2NlQ>
MDCK  M1;J[WZ2dmO2aX;uJGF{e2G7 M3nReVExKML3TR?= MVKyOEBp NXzsOmJJTE2VTx?= NUnPV3hkfXC{ZXf1cIF1\XNidHjlJIV5eHKnc4Ppc44hd2ZiVFfGMe6zOSCjbnSgR3RITsLi MYWyOlIxOjN3Mh?=
MDCK  M{HLc2Z2dmO2aX;uJGF{e2G7 NF:yS28yOCEEtV2= NH;BXGkzPCCq NXL0flA5TE2VTx?= NVLoPFhDcW6qaXLpeJMhfGinIHnuZ5Jm[XOnZDDlfJBz\XO|aX;uJI9nKE[QIHPheZNm\CCkeTDUS2Yu|rJz MVKyOlIxOjN3Mh?=
Spinal cords  NXjmRWplTnWwY4Tpc44hSXO|YYm= M1S4TVHDqM7:TR?= MX6zNEBucW5? NHLjdox{fGmvdXzheIV{KGODTWCgcIV3\Wy| M2q0NlI3OTJ4OUK2
BeWo  NUj0N4NVTnWwY4Tpc44hSXO|YYm= M1jLeFI26oDLzszN MX[yOE81QC95MjDo MX3s[YFleyC2bzDhckBqdmO{ZXHz[UBqdiC2aHWg[ZhxemW|c3nvckBw\iCxdHjldkBnfXOrb36gcYFzc2W{cx?= NH;lUGQzPjB3M{W0PS=>
bovine oocytes NFO4bXdHfW6ldHnvckBCe3OjeR?= NWjxXG1HOTBywrFOwG0> NYPkOm9COTMEoHi= M2jSXIlvcGmkaYTzJJRp\SCnZn\lZ5Qhd2ZiTmDQRUBidmRxb4KgUnBRSyC2bzDzeIlufWyjdHWgdoV{fW2ydHnvckBw\iCvZXnvd4l{ M1jnblI3ODVzNkGx
Caco-2  M2j6VmZ2dmO2aX;uJGF{e2G7 M1z1bFAvOS9zL{GwJO69VQ>? NXr2c29uOjEEoH3pci=> Mli0bY5lfWOnczDhJIRwe2VvZHXw[Y5l\W62IHnuZ5Jm[XOnIHnuJIlvfHKjY3XscJVt[XJiY1HNVEBt\X[nbIO= MV2yOlA1QTFyMh?=
Caco-2  MV7GeY5kfGmxbjDBd5NigQ>? NV:5RYprOC5zL{GvNVAh|ryP MWSyOEBp NH;TNIlqdmO{ZXHz[ZMhVVKSMjDwdo91\WmwIHzleoVt NIPFSmIzPjB2OUGwNi=>
AML-12  M{WwcmZ2dmO2aX;uJGF{e2G7 NX2zTGE3OjBizszN NHXQTmo{KGh? M4rmWpVxemWpdXzheIV{KHSqZTDwbI9{eGixconsZZRqd25ibHX2[Yx{KGG2IGTodk01OTFiYX7kJHNmei12OUO= MoPBNlYxPDh7OEW=
AML-12  NIDlSVBHfW6ldHnvckBCe3OjeR?= NEPMXXkzOCEQvF2= MlO4NU05KGh? MWjpcoNz\WG|ZYOg[4x2[2:|ZTDwdo9lfWO2aX;u MlfjNlYxPDh7OEW=
AML-12  MnXlSpVv[3Srb36gRZN{[Xl? MmfJNlAh|ryP NVnFTHVvOyCq MWL1dE1z\We3bHH0[ZPDqFCpY{HhMOKhWGWyY3usJIFv\MLiR{\wZ:KhdVKQQTDs[ZZmdHN? M2rK[VI3ODR6OUi1
AML-12  MVjGeY5kfGmxbjDBd5NigQ>? NUGwVpdmOjBizszN M{XieFMhcA>? NHiwW2xqdmS3Y3XzJJRp\SCmZYDoc5NxcG:{eXzheIlwdiCxZjDDVnREOsLi MX:yOlA1QDl6NR?=
RBMECs M{nMSGZ2dmO2aX;uJGF{e2G7 Mo\iOeKh|ryP M3K2NVEhcA>? MVvpcohq[mm2czDFUWFRNUmLLXnu[JVk\WRiaX7hZ5RqfmG2aX;uJI9nKFKjcEJCpC=> NWe2RlNyOjZyNES2OlM>
EndoC-βH1 MoLMSpVv[3Srb36gRZN{[Xl? NEf3O3Q2yqEQvF2= NGTqfHUyKGh? NYP0NJZleG:2ZX70bYF1\XNiZ3z1Z49{\S2rbnT1Z4VlKGmwc4XsbY4he2WlcnX0bY9vKGmwIITo[UBxemW|ZX7j[UBw\iCpbIXjc5Nm M{S3cVI3ODJ6NU[y
EndoC-βH1 MWDGeY5kfGmxbjDBd5NigQ>? NGHVTIw2yqEQvF2= NVLNXoQyOSCq Mm\vcIVi\HNidH:gZUB{fHKxbnegZ2FOWCCrbnPy[YF{\Q>? MmTYNlYxOjh3NkK=
SH-SY5Y NH3LfZZHfW6ldHnvckBCe3OjeR?= NXexSJp[OzBizszN M2jZVlMxKG2rbh?= M2\CNGROW09? M4O1dpNq\26rZnnjZY51dHliaX7jdoVie2W|IITo[UBi[3SrdnH0bY9vKG:oIGDLRS=> Mnv3NlYxOjVzM{e=
PC-3 NVX4PXZ{TnWwY4Tpc44hSXO|YYm= Mo\nOFAhyrWP NW\ETGdGOiCq MmW3SG1UVw>? MnvjcIVi\HNidH:gVHAzSSCjY4TpeoF1cW:w MYqyOlAzOzh|Nh?=
PC-3 MYTD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M2fnc|QxKML3TR?= MVqyOE81QC95MjDo MWHEUXNQ MkPZ[IVkemWjc3XzJINmdGxidnnhZoltcXS7IITpcYUh\GWyZX7k[Y51dHl? M1nxUFI3ODJ|OEO2
SCG MUTGeY5kfGmxbjDBd5NigQ>? NV3KVI5LOjBizszNxsA> MmDzSG1UVw>? NGO1XXVz\X[ncoPpZox6KHO3cIDy[ZN{\XNiSVvWJJdqfGhiYTDJR|UxKG:oIEK0MlQh|ryP MVSyOVk3OjF|Mh?=
HEK-293 NHXSeWRHfW6ldHnvckBCe3OjeR?= MlnZN|Uh|ryPwrC= M2HFNGROW09? Mo\IbY5lfWOnczDhJINwdnOyaXP1c5V{KOLCnHnuZYN1cX[jdHnvcwKBpSCxZjD0bIUhU3Z{LkGgZ5VzemWwdB?= NY\QRXg5OjV7NkKxN|I>
SCG NVTsOVFFTnWwY4Tpc44hSXO|YYm= M4HaNFExOCEQvF5CpC=> M2HX[GROW09? Mn:3doVlfWOnczD0bIUh\XilaYThZoltcXS7IH;mJHNETyCwZYXyc45{ M37hUlI2QTZ{MUOy
PCCL3 NYfCO5RSTnWwY4Tpc44hSXO|YYm= MVWxNEDDvU1? MWOyOEBp NEPQT4JmdmijbnPld{BFfU:6MjDwdo9ud3SncjD0doFve2O{aYD0bY9vKGGldHn2bZR6yqEkgJu= MkPPNlU6PjB7NU[=
3T3-L1 preadipocytes NXfldYMxTnWwY4Tpc44hSXO|YYm= MXqxNEDPxE4EoB?= MlT1NVIhcA>? M1;FcYlv\HWlZYOgR3JGSiCyaH;zdIhwenmuYYTpc44h[W6mIFOvSWJR|rJiZYjwdoV{e2mxbh?= Mmf6NlU6OjhyNUi=
H295R  NYTTR4hSTnWwY4Tpc44hSXO|YYm= NFrkR3gyOMLizszN NVzrbWYxPDkEoHi= NFPnZm5qdmO{ZXHz[ZMhe3Sncn;p[EBu\XSjYn;sbZRmeyCrbjD0bIUh[W6mcn;n[Y4tKG2rbnXyZYxwNSCjbnSg[4x2[2:lb4L0bYNwcWRicHH0bJdigXN? M1q4WFI2QDZ7NUW2
PBMC MVnGeY5kfGmxbjDBd5NigQ>? NIP5T282OMLizszN MmK1NlTDqGkEoB?= Mne5bY5pcWKrdIOgeIhmKGmwY4LlZZNm\CC|ZXPy[ZRqd25ib3[gWG5HKGmwZIXj[YQh[nlidHjlJGRRTQ>? NF\WSlczPTh4NkC3PS=>
GLUTag  NGLVdIdHfW6ldHnvckBCe3OjeR?= NF;ycJQyOOLCidM1US=> MUSwM|IwPCCq MULzeIlufWyjdHXzJGdNWC1zIIPlZ5JmfGmxbjDjc5Rz\WG2ZXSge4l1cCCLQl3Y M{jWdVI2QDN{NkOx
GLUTag  NUHhNXF6TnWwY4Tpc44hSXO|YYm= MU[xNQKBkcL3TR?= NGTSd2k1KGh? NGHPWpZqdmO{ZXHz[ZMhfGinIIDDVmVDKGyndnXsd{B4cXSqIITo[UBKSk2[ M{XyWFI2QDN{NkOx
BAECs M2\nbGZ2dmO2aX;uJGF{e2G7 MViyOUDPxE1? MUSyOEBp M2TXNoVvcGGwY3XzJJRp\SCjY4TpeoF1cW:wIH;mJHBRSVMQsTDifUA2KM7:TTDy[ZN3\XKjdILvcEwhXDSKUzygc5IhPC2SQWC= MmHQNlU4QTh6Mk[=
PC12 NXnwWFl3TnWwY4Tpc44hSXO|YYm= MX6yOeKh|ryP MkTEOFghcA>? NGP4bYZi[3SrdnH0[ZMh[0GPUB?= MnTmNlU4Pjl|MEW=
GH3 MlL1SpVv[3Srb36gRZN{[Xl? MUOxxsDPxE1? NED6OXU3NWh? NFvVR4NifHSnboXheIV{KHSqZTDjc5Jz\WyjdHnvckBj\XS5ZXXuJHBTVCCjbnSgRo1idDFiZYjwdoV{e2mxbh?= M2ewN|I2PzJ5MEG4
GH3 NXP6TlJoTnWwY4Tpc44hSXO|YYm= M3vjTFHDqM7:TR?= NEHmdoU3NWh? NEDMfoNqdmS3Y3XzJHBTVCCjbnSgRo1idDFuIHL1eEBvd3RiQ3zvZ4stKG2UTlGg[ZhxemW|c3nvci=> MmHaNlU4OjdyMUi=
BeWo NFXXOnhHfW6ldHnvckBCe3OjeR?= NWCyT3NTOTEkgJtOwG3DqA>? NH2zR4U4OiCq M1;ZSWROW09? NXzZVpFmdWWmaXH0[ZMhSmWZbzDj[YxtKGSrZn\ldoVvfGmjdHnvci=> M3r6[VI2PzF|NEK1
oocytes MlLkSpVv[3Srb36gRZN{[Xl? NHPPW3M2KM7:TR?= MmTvNlQhcA>? MYHheJRmdnWjdHXzJJJpNWmwc4XsbY4h[WO2aX;uJI9vKG:xY4n0[UBIXkKGIIPp[45q\mmlYX70cJnDqA>? MnzTNlU4ODd6NUS=
SC NEXofotHfW6ldHnvckBCe3OjeR?= M4X4cVAvPSEQvF2= NInnToYzPCCq NWHHZZhodWmvaXPrd{B1cGViZX\m[YN1KG:oIHPBUXAh[W6jbH;nd{BwdiCRMTDhcoQhVUKSIHX4dJJme3Orb36= MUSyOVcxPTh5NB?=
SC Mn3ISpVv[3Srb36gRZN{[Xl? NIfJRWUxNjVizszN NIjpVJU4OiCq NIqzV2lqdmO{ZXHz[ZMh[m:2aDDLdo95NTJyIHHu[EBQOSCneIDy[ZN{cW:wIHnuJIF5d25vcnXsZZRm\CCVQ4OgZpV1KG:wbImgT5JwgC1{MNMg Mni1NlU4ODV6N{S=
UACC-647  NFHsVWZHfW6ldHnvckBCe3OjeR?= NUfGRZlYTE2VTx?= Mn7DcIVi\HNidH:gZUBzcXOnIHnuJINCVVBibHX2[Yx{KCiHQ{WwxsA:yqB{MD6zPeKh|ryPKR?= NX\kOJdJOjV5MEOwNlU>
UACC-647  NHfhVolHfW6ldHnvckBCe3OjeR?= M17yelExyqEQvF2= NIfmTFgyPSCvaX6= NFPxUmtFVVOR MYrpcohq[mm2czDFVmsheGixc4Doc5J6dGG2aX;u MXuyOVcxOzB{NR?=
UACC-647  NWfYZYJiTnWwY4Tpc44hSXO|YYm= NIDvOFEyOMLizszN MojjNVUhdWmw MVHEUXNQ M2PkSYlv[3KnYYPld{BmTUZ{IIDoc5NxcG:{eXzheIlwdiCuZY\lcJPDqA>? NYrpenlmOjV5MEOwNlU>
SH-SY5Y  NYjpWpVITnWwY4Tpc44hSXO|YYm= NY\hbnZNOTEEoN88US=> NFXLXVUyyqCqwrC= NGfmRVRqdmO{ZXHz[ZMhVFWFIHHjeIl3cXS7 NFHjbGkzPTV7N{SzNy=>
SH-SY5Y  NE\qUo1HfW6ldHnvckBCe3OjeR?= MXGxNOKh|ryP M{\hdFHDqGkEoB?= Ml7SbY5kemWjc3XzJGFISzFibWLORUBt\X[nbB?= MYOyOVU6PzR|Mx?=
hADSCs MWXGeY5kfGmxbjDBd5NigQ>? M{jEXVXjiIoEtV2= NFXwdmU{OCCvaX6= NEfL[IFqdmO{ZXHz[ZMh[0GPUDDs[ZZmdHN? M1vJc|I2PTlzOUC4
HEK293  MVvGeY5kfGmxbjDBd5NigQ>? NVjHSoEzPeLCidM1US=> M3nFOVMxKG2rbh?= MnPQbY5kemWjc3XzJINCVVBibHX2[Yx{ MnjvNlU2QTF7MEi=
3T3-L1 Ml7HSpVv[3Srb36gRZN{[Xl? MmLRNk42NzVizszN NYXPNGRGOjRiaNMg NWrJXYpEe2mpbnnmbYNidnSueTDk[YNz\WG|ZYOgRXRIVCCycn;0[YlvKGW6cILld5Nqd25iYYSgZYxtKGSxc3XzJJRme3SnZB?= Mn\5NlU2QTB3OUe=
OCI-Ly1  NFLlNXpHfW6ldHnvckBCe3OjeR?= M4jhZlQxyqEQvF2= M3W4ZlHDqGkEoB?= NH3mdW5FVVOR MWjpcoR2[2W|IITo[UBqdmO{ZX3lcpQhd2ZiY1HNVEBkd26lZX70doF1cW:wcx?= NX23NpNKOjV3N{[yNlA>
OCI-Ly18  MYfGeY5kfGmxbjDBd5NigQ>? M17rNlQxyqEQvF2= NWHFfYRFOcLiaNMg MXvEUXNQ MoPibY5lfWOnczD0bIUhcW6lcnXt[Y51KG:oIHPBUXAh[2:wY3XueJJifGmxboO= NXi1TpQ6OjV3N{[yNlA>
BeWo MonKSpVv[3Srb36gRZN{[Xl? NWP0TnRPOjEEoNM1US=> NGTsOIs1QMLiaB?= NV;vU4NVTE2VTx?= M4\TfIlv[3KnYYPld{B1cGViZHnm[oVz\W62aXH0bY9vKG:oIFLlW48h[2WubIO= Mkj3NlU2PjZ5NEC=
BeWo MX;GeY5kfGmxbjDBd5NigQ>? MnXRNlDDqML3TR?= Mn;QOFjDqGh? NH7z[mRFVVOR NULTUFdwcW6lcnXhd4V{KHSqZTDh[Ihme2mxbjDv[kBVUFBvMTDtc45w[3m2ZYO= MojCNlU2PjZ5NEC=
LNCaP  M4Lne2Z2dmO2aX;uJGF{e2G7 MVqxNOKh|ryP MnfMNVIhcMLi NWPwcoxKTE2VTx?= NWD5VVJFcW6mdXPld{BiKGS{YX3heIlkKGmwY4LlZZNmKG:oIFPSSWIyKGGldHn2bZR6 MWKyOVU1QDB7OR?=
ThGCs  NFjLV4RHfW6ldHnvckBCe3OjeR?= MoDyNVDjiIsQvF2= MmDGOQKBkmh? NF\aVHFifWevZX70d{BJUUZzQTDs[ZZmdHNidHjheEB4\XKnIIP0bY12dGG2ZXSgZpkhS2:FbEK= NWTYR4FQOjV2M{OwNlc>
ThGCs  NF\6[2hHfW6ldHnvckBCe3OjeR?= M3zaVVEx6oDMzszN NHrXVHQ16oDMaB?= MULpcoNz\WG|ZYOgR49EdDJvaX7keYNm\CCHRF6yxsBo\W6nIHX4dJJme3Orb36= MUOyOVQ{OzB{Nx?=
ThGCs  NFfWSVlHfW6ldHnvckBCe3OjeR?= NWPGcmFlOTEkgJtOwG0> Mny4N{Bp NWnG[nV{cW6qaXLpeJMhfGinIHXm[oVkfCCxZjDINm8zKG:wIFXEUlIhdVKQQR?= M3;Mb|I2PDN|MEK3
RBMECs MYrGeY5kfGmxbjDBd5NigQ>? NV3NNFhXOC5yNT:wMlUwPSEQvF2= NWfucHFSOC5{NTDo NH7Qc2VqdmO{ZXHz[ZMh[0GPUDDjc45k\W62cnH0bY9v MV[yOVQyPjZ3MR?=
RBMECs NIPkem1HfW6ldHnvckBCe3OjeR?= MXy1xsDPxE1? MmTzNUBp MVnicI9kc3NidHjlJIFkfGm4YYTpc44hd2ZiUnjvRU9TV0ONIHnu[JVk\WRiYomgSW1CWC2LSR?= M1G1cFI2PDF4NkWx
RBMECs NGHPcmlHfW6ldHnvckBCe3OjeR?= NFqwRWQ2yqEQvF2= Mn;KNUBp MVjwdoV3\W62czD0bIUhTU2DUD3JTU1qdmS3Y3XkJHRGTVJidnHseYUh\GWlcnXhd4U> M1yxZlI2PDF4NkWx
RBMECs MWnGeY5kfGmxbjDBd5NigQ>? Ml[5OeKh|ryP Moe0NUBp M2fv[5Bz\X[nboTzJJRp\SCrbnPy[YF{\SCrbjDIVnAh\my3eDDhZ5Jwe3NidHjlJGJVSiCrbnT1Z4VlKGK7IDDFUWFRNUmL NWS1TGJOOjV2MU[2OVE>
RBMECs NF\IRZdHfW6ldHnvckBCe3OjeR?= MmCyOeKh|ryP MknWNUBp MlvBbY5pcWKrdIOgeIhmKGSnY4LlZZNm\CCxZjDhcY92dnRib3[gXm8uOSCrbjDNSpMhcW6mdXPl[EBjgSCHTVHQMWlK M{i3fFI2PDF4NkWx
RBMECs NXfBTGs5TnWwY4Tpc44hSXO|YYm= Mk\XOeKh|ryP NFSzSnQyKGh? NHPOUFdz\X[ncoPld{B1cGViY3jhcodmeyCrbjDaU{0yKGSrc4TybYJ2fGmxbjDz[YVvKHerdHigSW1CWC2LSTD0doVifG2nboS= MX6yOVQyPjZ3MR?=
RBMECs Mn7XSpVv[3Srb36gRZN{[Xl? MmHVOeKh|ryP NWrNeHdsOSCq NX;2[Fk5[myxY3vzJJRp\SCHTVHQMWlKNWmwZIXj[YQh[2ijbnflJIlvKE2OQzDwbI9{eGixconsZZRqd25? NX\lTmhwOjV2MU[2OVE>
RBMECs M4PTbGZ2dmO2aX;uJGF{e2G7 MXS1xsDPxE1? MUCxJIg> MU\icI9kc3NidHjlJIFkfGmwIHP5eI9{c2WuZYTvckBz\WG{cnHu[4Vu\W62IIPl[Y4hf2m2aDDFUWFRNUmLIITy[YF1dWWwdNMg MX6yOVQyPjZ3MR?=
Primary bovine chondrocytes MmP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLES2hXPc7:TR?= M2jL[lQ5KGh? M{fBXpJmfmW{c3XzJJRp\SCrbnjpZol1d3K7IHXm[oVkfCCxZjDj[Yxm[2:6aXKgc44heHKxbHnm[ZJifGmxbjDpckBoem:5dHigdIxifGViY3jvcoRzd2O7dHXz NXrYUoY3OjV2ME[wNVY>
EM1  NHzmS|JHfW6ldHnvckBCe3OjeR?= M1ezWVE26oDMzszN NYKwUox7PDhiaB?= NF7qT2lz\WS3Y3XzJJRp\SCneIDy[ZN{cW:wIH;mxsBNUUcEoH;yxsBRXEeVMtMgbY7DqEODTGKtJI9zyqCHUFHDNk1{cWynbnPl[EBGVTFiY3XscJPDqA>? MkDJNlU{Pzh4NkG=
BeWo  NFvCOZlHfW6ldHnvckBCe3OjeR?= M4HK[VIxyqEEtV2= MVO0POKhcMLi M{[2ZWROW00EoB?= M3nsR4lv[3KnYYPld{B1cGViYnX0ZU1pS0dicnXs[YF{\Q>? Ml64NlU{PjJ{NkC=
BeWo  NIm1Z4FHfW6ldHnvckBCe3OjeR?= MoOzNlDDqML3TR?= MYG0POKhcMLi NUHsTolMTE2VT9Mg NHnUem5ld3ewcnXneYxifGW|IITo[UBt\X[nbDDv[kBVVUWPRkG2 NH;hdmczPTN4MkK2NC=>
BeWo  M4nqemZ2dmO2aX;uJGF{e2G7 Ml;pNlDDqML3TR?= NIPkSpk1QMLiaNMg Mm\LSG1UV8Li NEj0XGlld3ewcnXneYxifGW|IITo[UBt\X[nbDDv[kBIS01vMR?= MnLMNlU{PjJ{NkC=
granulosa cells MVXGeY5kfGmxbjDBd5NigQ>? MWSxNEDPxE1? MnL4NVIwOjRiaB?= NVPjb405cW6lcnXhd4V{KHSqZTDs[ZZmdHNib3dCpHJIWzMEoH3SUmE> NXHPfW04OjV|M{mxNFU>
granulosa cells MUHGeY5kfGmxbjDBd5NigQ>? NGDUOVIyOCEQvF2= MV:xNk8zPCCq NH65R5BqdmO{ZXHz[ZMhfGinIHzleoVteyCxZjDy[ZBwenSncjDhZ5Rqfmm2eTDmc5IhfGinIHzvcodme3RiZoLh[41mdnRiKPMIllg2PC9tMUjSS3MzNkyXQzm= MnP6NlU{OzlzMEW=
granulosa cells Mn6xSpVv[3Srb36gRZN{[Xl? NYfnOGNxOTBizszN MYeyOEBp NUCwUJlscW6lcnXhd4V{KHSqZTDpcpRmdnOrdImgc4YhTE6DL4Dyc5RmcW5iY3;tdIxmgA>? M1X6OVI2OzN7MUC1
granulosa cells NGDFO3lHfW6ldHnvckBCe3OjeR?= NI\ZSJQyOCEQvF2= NVLYR2tPOjRiaB?= MX7pcoNz\WG|ZYOgeIhmKGyndnXsd{Bw\iCUR2OyJJBzd22xdHXyJIFkfGm4aYT5 NYHTOWJkOjV|M{mxNFU>
SK-N-AS  NF\PeGJE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MkPTNVAh|ryPwrC= MW[yOE81QCCq M2mzdIVvcGGwY3XzJJRqdWVvZHXw[Y5l\W62bImgZ4VtdHWuYYKgeoli[mmuaYT5xsA> MVuyOVI3PjB4Mx?=
SK-N-AS  M4TwdWZ2dmO2aX;uJGF{e2G7 MXixNEDPxE4EoB?= MYqyOEBp MY\pcoNz\WG|ZYOgeIhmKGODTWCgcIV3\Wy|wrC= MnfqNlUzPjZyNkO=
SK-N-AS  MWLGeY5kfGmxbjDBd5NigQ>? M2DubFExKM7:TdMg MnPCNlQhcA>? MYLpcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ib3[gZ5lkdGmwIFSx MlvFNlUzPjZyNkO=
SK-N-AS  M3m2T2Z2dmO2aX;uJGF{e2G7 M4KyfVExKM7:TdMg MnPzN|AhdWmw NYn3[VBtcW6mdXPld{BxcG:|cHjvdplt[XSrb36gc4Yh|rJvY3H0[Y5qdiBqc3XyOlc2MSxicD3HV2s{|rJiKIPldlkqKGGwZDDjc45kd22rdHHueEBpcWeqZYKgcIV3\Wy|IH;mJIFkfGm4ZTygeY5xcG:|cHjvdplt[XSnZDyg{tIu[2G2ZX7pci=> MVWyOVI3PjB4Mx?=
SK-N-AS  M3jFcGZ2dmO2aX;uJGF{e2G7 MmWxNVAh|ryPwrC= NFPQWWEyOC9|MD:2NEBucW5? MV3pcoNz\WG|ZYOgcIV3\Wy|IH;mJJAu|rJvY3H0[Y5qdiBqc3XyOlc2MSCjbnSgbY5lfWOnczDhZ4N2dXWuYYTpc44hd2ZicD5Otk1k[XSnbnnuJEh{\XJ4N{WpJIlvKCiyZYLpLY52[2ynYYKgdoVocW:wcx?= NF3H[nAzPTJ4NkC2Ny=>
SK-N-SH MoLoR4VtdCCYaXHibYxqfHliQYPzZZk> NVLmVWdSOTBizszNxsA> NGnIVHg1QCCq Ml7C[Y5p[W6lZYOgV2suVi2VSDDu[ZVzd2KuYYP0c41iKGOnbHygeoli[mmuaYT5 NYG4eWhQOjV{Nk[wOlM>
HEK‐CFTR M2SxS2Z2dmO2aX;uJGF{e2G7 M{T3NlLjiJN3MNMg{txO MoLRNE0yOiCvaX6= M3T0TGROW00EoB?= MVvpcoR2[2W|IHGg[I9{\eLCkHTldIVv\GWwdDDpc4Rq\GViZX\mcJV5yqB? MYWyOVI3OzJyNx?=
L6 NY\BSW1OTnWwY4Tpc44hSXO|YYm= NUO3c5ZlPDBiwsXN NIPXd4szPCCq MWXpcohq[mm2czDEUWgyNWmwZIXj[YQhSWu2IHHjeIl3[XSrb36= MnzJNlUzPDd3NUC=
MIN6  NVLOdIpOTnWwY4Tpc44hSXO|YYm= NIHDWVkyOCEQvF5CpC=> MnHYN{Bp NH3GOpFqdmO{ZXHz[ZMhTDNibWLORUBmgHC{ZYPzbY9v NV3n[XNmOjV{NEGxNlQ>
ventricular cardiomyocytes  NVnlXHRxTnWwY4Tpc44hSXO|YYm= MlnPNE4xOS1zMDFOwG0> NFvRfVNqdmO{ZXHz[ZMhKGODTWCgZYNkfW23bHH0bY9v MoHGNlUzODNzMUO=
ventricular cardiomyocytes  M2O4U2Z2dmO2aX;uJGF{e2G7 M4TxWVAvODFvMUCg{txO MWrleo9s\XNiYX6gbY5wfHKxcHnjJJJme3CxboPlJFEzOMLzMUWlJIFjd3[nIHLhd4FtKHerdHigZY4hTUN3MNMgc4YhOi5{INM1US=> MYGyOVIxOzFzMx?=
BeWo  MnzISpVv[3Srb36gRZN{[Xl? NFXMN5UzOCEEtV2= NVvofWV{PDhiaB?= M4njeGROW00EoB?= NFrOVpJqdmS3Y3XzJINmdGxiZoXzbY9v NHvpToozPTF6NES3Oy=>
THP-1  MWTGeY5kfGmxbjDBd5NigQ>? M3fVW|EwOTBizszN MYqyxsBp NVG4[GpwTE2VT9Mg NEXnWXB{fXCycnXzd4V{KE2FUD2xJJBzd2S3Y4Tpc47DqA>? MUOyOVE2PDh6Mh?=
Huh-7 M2DFdmZ2dmO2aX;uJGF{e2G7 NIfWXGYxNTJyIN88US=> NV\wdXl[OiCqwrC= MoXYdoV{fWy2czDpckBiKGSxc3Wt[IVx\W6mZX70JIlv[3KnYYPlJIlvKGNvTYnjJIV5eHKnc4Ppc44h[XRidHjlJJBzd3SnaX6gZY5lKG2UTlGgcIV3\Wy| NFX3fYUzPTFyOUizOC=>
C6 NWfBOmF4TnWwY4Tpc44hSXO|YYm= NUDkNHdHOTBizszNxsA> NUTxVphrOjBibXnu NHy1XVRqdmO{ZXHz[ZMh[0GPUDDhZ4N2dXWuYYTpc44> Ml62NlUxPjl2MUe=
SW480 MVTGeY5kfGmxbjDBd5NigQ>? NELPVI41OMLizszN Mn2wOFjDqGh? NFfWUnZFVVOR MWrhZ5RqfmG2ZYOgVHAzSQ>? NIOzNXQzPDl7N{S1NS=>
HT-29  NYjjPYdiTnWwY4Tpc44hSXO|YYm= NGKyVHQ1OMLizszN M1q5eFQ5yqCq NETJfXhFVVOR MlTvZYN1cX[jdHXzJHBROkF? NYD2XG9XOjR7OUe0OVE>
SW480 M3PKemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4Tse|QxyqEQvF2= MmDnNE04OiCq M3q5[GROW09? M2PRcolvcGmkaYTzJINmdGxiZ4Lve5RpKHSrbXWg[IVx\W6mZX70cJk> NUHTc3BpOjR7OUe0OVE>
HT-29  MlnoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX60NOKh|ryP NH7ZPXUxNTd{IHi= Ml3MSG1UVw>? NETucopqdmirYnn0d{Bk\WyuIHfyc5d1cCC2aX3lJIRmeGWwZHXueIx6 MWSyOFk6PzR3MR?=
SW480 M3e5UmZ2dmO2aX;uJGF{e2G7 MWq0NOKh|ryP NH;2bIE4KGR? M4HENmROW09? MYny[YR2[2W|IHPvcI9vd3OyaHXy[UBnd3KvYYTpc44h[2GyYXLpcIl1gcLi MX[yOFk6PzR3MR?=
HT-29  MlHhSpVv[3Srb36gRZN{[Xl? NY[zWXQ2PDEEoN88US=> M2rsfFch\A>? MmXYSG1UVw>? MUHy[YR2[2W|IHPvcI9vd3OyaHXy[UBnd3KvYYTpc44h[2GyYXLpcIl1gcLi M3W1W|I1QTl5NEWx
SW480 MVnBdI9xfG:|aYOgRZN{[Xl? Mn3XOFDDqM7:TR?= NXe5V4NqPDkEoHi= MV\EUXNQ M3TPOolv\HWlZYOgZY4h[WO2aY\heIlwdiCxZjDjZZNx[XOnIEOvOy=> MV[yOFk6PzR3MR?=
HT-29  M3rhbmFxd3C2b4Ppd{BCe3OjeR?= NUjQU3VtPDEEoN88US=> MUW0POKhcA>? NWnVU|hWTE2VTx?= NYK5U|UzcW6mdXPld{BidiCjY4TpeoF1cW:wIH;mJINie3Cjc3WgN{84 NF\Z[JAzPDl7N{S1NS=>
SW480 M3XpW2Fxd3C2b4Ppd{BCe3OjeR?= M{nRRlQxyqEQvF2= NFLuWGk1QMLiaB?= MYLEUXNQ MlnObY5lfWOnczDjbIFv\2W|IHnuJJRp\SCyaH;zdIhwenmuYYTpc44he3SjdIXzJI9nKFCSMlGgeIFz\2W2cx?= MX:yOFk6PzR3MR?=
HT-29  NIW1TGhCeG:ydH;zbZMhSXO|YYm= MmC2OFDDqM7:TR?= Mn7TOFjDqGh? MYTEUXNQ NEX4SZdqdmS3Y3XzJINp[W6pZYOgbY4hfGinIIDoc5NxcG:{eXzheIlwdiC|dHH0eZMhd2ZiUGCyRUB1[XKpZYTz MlzQNlQ6QTd2NUG=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
cleaved caspase-3 / caspase-3; 

PubMed: 30863177     


Toledo, NK-92, RL, and Farage cells were treated with 30 μM of forskolin for 48 hours, then the cells were harvested for Western blotting to assess the expression of total or cleaved caspase-3

cleaved caspase-9 / caspase-9 ; 

PubMed: 30863177     


Toledo, NK-92, RL, and Farage cells were treated with 30 μM of forskolin for 48 hours, then the cells were harvested for Western blotting to assess the expression of total or cleaved caspase-9.

β-catenin; 

PubMed: 30863177     


(A, B) The protein expression of cytoplasmic and nuclear β-catenin in Toledo and NK-92 cells in the presence of 0, 10, 20, or 40 μM forskolin was detected by Western blotting.

c-myc / Cyclin D1; 

PubMed: 30863177     


(C, D) Western blotting analysis of the total protein expression of c-myc and cyclin D1 influenced by 0, 10, 20, or 40 μM of forskolin in Toledo and NK-92 cells (n=3, *P<0.05, forskolin group vs control group).

pS6K1 / S6K1 / pCREB / CREB; 

PubMed: 31112131     


Forskolin inhibits mTORC1 in multiple cell lines. PC3, LNcap/AR, H1299, H1944, MDA-MB-231, MEF, HAP1, COS7, HeLa, MIA Paca-2, and PANC-1 were treated with or without 10 μM forskolin for 1 h and mTORC1 activity, CREB phosphorylation, and loading controls were analyzed.

p-JNK / JNK / P-p38 / p38; 

PubMed: 20070884     


L929 cells were pretreated with forskolin (10 μM) for various times as indicated, followed by stimulation with or without 10 ng/ml TNF-α for 15 min.

30863177 31112131 20070884
Immunofluorescence
5hmC; 

PubMed: 29239726     


Schwann cells were treated with forskolin (10 μM) for 3 hr followed by washout. 5hmC induction was detected at of 0, 3, and 24 hr time points following treatment. Cells continuously treated with forskolin (5, 10 μM) for 24 hr showed comparable 5hmC levels. Scale bar = 20 μm. 

Fe(II); 

PubMed: 29239726     


AMP (100 mM) treatment for 4 hr did not induce labile Fe(II) while AC activators (forskolin (100 mM), bicarbonate (50 mM)) and PDE inhibitors (caffeine (100 mM), IBMX (100 mM)) increased labile Fe(II) detected by Trx-Puro probes.

CYP17A1 / CYP21A2; 

PubMed: 25334044     


H295R cells were treated with 8-Br-cAMP or forskolin for 48 h under growth conditions, and fixed with 4% paraformaldehyde. (A) Immunostaining for CYP17A1. Red staining shows the anti-CYP17A1 antibody and blue staining shows DAPI (cell nuclei). (B) Immunostaining for CYP21A2. Red staining shows the anti-CYP21A2 antibody and blue staining shows DAPI (cell nuclei). Scale bars represent 100 µm.

29239726 25334044
Growth inhibition assay
Cell viability; 

PubMed: 30863177     


(C) MTT assay was conducted to test the cell growth after Toledo cells were administered 0, 20, 40, 80, or 160 μM of forskolin for 1, 2, 3, 4, 5, or 6 days. (D) Toledo cells were administered 0, 20, 40, 80, or 160 μM of forskolin for 48 hours, then MTT assay was used to evaluate the IC50 of forskolin. (F) MTT assay was conducted to test the cell growth after NK-92 cells were administered 0, 20, 40, 80, or 160 μM of forskolin for 1, 2, 3, 4, 5, or 6 days. (G) NK-92 cells were administered 0, 20, 40, 80, or 160 μM of forskolin for 48 hours, then MTT assay was used to evaluate the IC50of forskolin. 

30863177

Protocol

Solubility (25°C)

In vitro DMSO 82 mg/mL (199.75 mM)
Water Insoluble
Ethanol '''37 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 410.5
Formula

C22H34O7

CAS No. 66575-29-9
Storage powder
in solvent
Synonyms Coleonol
Smiles CC(=O)OC1C(C2C(CCC(C2(C3(C1(OC(CC3=O)(C)C=C)C)O)C)O)(C)C)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04254705 Not yet recruiting Procedure: Rectal Biopsy Cystic Fibrosis Universitaire Ziekenhuizen Leuven|Vertex Pharmaceuticals Incorporated|KU Leuven|University of Lisbon March 1 2020 Not Applicable
NCT02807415 Completed Drug: Lumacaftor plus Ivacaftor Cystic Fibrosis Hannover Medical School|Heidelberg University|University of Giessen June 1 2016 --
NCT02586883 Unknown status Other: bronchial ddp test Idiopathic Dilation of the Bronchi Assistance Publique - Hôpitaux de Paris March 29 2016 Not Applicable
NCT03652090 Completed Procedure: cell sampling Cystic Fibrosis Institut National de la Santé Et de la Recherche Médicale France|ABCF2 September 1 2010 --

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

cAMP Signaling Pathway Map

Tags: buy Colforsin (Forskolin) | Colforsin (Forskolin) supplier | purchase Colforsin (Forskolin) | Colforsin (Forskolin) cost | Colforsin (Forskolin) manufacturer | order Colforsin (Forskolin) | Colforsin (Forskolin) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID